Objective To evaluate the clinical efficacy and adverse reactions for long-term application of recombinant human endostatin with concurrent hormone and radiation therapy for advanced prostate cancer. Methods 28 patients with histologically confirmed advanced prostate cancer were divided into experimental (18 patients) and control groups (10 patients). The experimental group was treated with endostatin combined with concurrent hormone and radiation therapy, and the control group was treated with hormones and radiotherapy. The efficacy and adverse reactions for both groups were observed. Results The serum levels of PSA and TPSA in experimental group and control group after treatment were lower than that of pretreatment (P <0.01), This indicated that two treatments were effective for prostate cancer. The serum levels of FPSA and TPSA in both experimental group and control group were decreased by a big margin in two months after treatment (P <0.01). The serum levels of FPSA and TPSA in experimental group at different times were lower than that of control group (P <0.01). The bone marrow suppression in experimental group mainly in white blood cells as the most important was significantly higher than that of control group (P<0.05). Conclusion The combined Endostatin with hormone and radiotherapy for prostate cancer treatment are superior to single treatment. The serum levels of FPSA and TPSA decline rapidly and maintaining a lower level for longer duration.